Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| bluebird bio Inc | BLUE | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 4.29 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.29 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 2.865 - 8.58 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 4.29 | USD |
bluebird bio Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 441.54M | 102.92M | 82.05M | $ 3.66M | $ - | -11.89 | -0.80 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 141.98k | 1.50% |
bluebird bio News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BLUE Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.65 | 4.705 | 4.26 | 4.51 | 5,719,196 | -0.36 | -7.74% |
| 1 Month | 5.41 | 5.44 | 4.00 | 4.71 | 4,244,615 | -1.12 | -20.7% |
| 3 Months | 6.67 | 8.52 | 4.00 | 5.83 | 3,892,417 | -2.38 | -35.68% |
| 6 Months | 5.83 | 8.58 | 4.00 | 6.39 | 3,912,901 | -1.54 | -26.42% |
| 1 Year | 5.08 | 8.58 | 2.865 | 5.51 | 5,412,526 | -0.79 | -15.55% |
| 3 Years | 48.87 | 73.50 | 2.865 | 14.38 | 2,823,047 | -44.58 | -91.22% |
| 5 Years | 180.90 | 199.70 | 2.865 | 30.21 | 2,003,075 | -176.61 | -97.63% |
bluebird bio Description
| bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates. |